Biotechnology & Genomics

Biotech's GLP-1 drug class (Ozempic, Wegovy, Mounjaro) alone represents a $100 billion+ annual market in 2025, growing at 50%+ per year as applications expand from diabetes and obesity into addiction, cardiovascular disease, and Alzheimer's. CRISPR gene editing therapies received FDA approval in 2023 for sickle cell disease, opening a new era. The global biotech market is valued at $1.5 trillion and growing at 14% CAGR.